Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx Inc (NQ: ARDX )

6.130 +0.300 (+5.15%)
Streaming Delayed Price Updated: 1:52 PM EDT, Aug 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,226,803
Open 5.870
Bid (Size) 6.120 (40)
Ask (Size) 6.130 (34)
Prev. Close 5.830
Today's Range 5.730 - 6.200
52wk Range 3.160 - 10.13
Shares Outstanding 103,119,010
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What 6 Analyst Ratings Have To Say About Ardelyx
Via Benzinga
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire

Performance

YTD
+1.32%
+1.32%
1 Month
+12.48%
+12.48%
3 Month
-33.01%
-33.01%
6 Month
-31.58%
-31.58%
1 Year
+63.47%
+63.47%

More News

Read More
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
From Ardelyx, Inc.
Via GlobeNewswire
Get Your Money Out of These 3 Biotech Stocks Before the End of July
Via InvestorPlace
Analyst Expectations For Ardelyx's Future
Via Benzinga
How Is The Market Feeling About Ardelyx?
Via Benzinga
What Analysts Are Saying About Ardelyx Stock
Via Benzinga
Ardelyx Files Lawsuit Over Medicare Drug Payment Rules, Claims It Will Limit Patient Access To Kidney Disease Treatment
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
From Ardelyx, Inc.
Via GlobeNewswire
Why Ardelyx Stock Is Dropping
Via Benzinga
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
From Ardelyx, Inc.
Via GlobeNewswire
3 Stocks Under $10 With the Potential to Make You a Millionaire
Via InvestorPlace
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Via InvestorPlace
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
From Ardelyx, Inc.
Via GlobeNewswire
The 3 Best Penny Stocks to Buy in May 2024
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
From Ardelyx, Inc.
Via GlobeNewswire
7 Cheap Penny Stocks to Buy Now: May 2024
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
From Ardelyx, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.